PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-142.73%
Both yoy net incomes decline, with AGEN at -115.62%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
55.79%
Less D&A growth vs. AGEN's 2747.43%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
71.34%
Some yoy growth while AGEN is negative at -100.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-22.08%
Negative yoy SBC while AGEN is 97.78%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
83.34%
Slight usage while AGEN is negative at -115.97%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.76%
A yoy AP increase while AGEN is negative at -164.91%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-41.25%
Both reduce yoy usage, with AGEN at -116.22%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-22.08%
Negative yoy while AGEN is 91.81%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
9.39%
Some CFO growth while AGEN is negative at -490.53%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.94%
We cut debt repayment yoy while AGEN is 96.60%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-35.14%
Negative yoy issuance while AGEN is 113.38%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.